213P - Epithelial tumors of the thymus: Prognostic factors and multidisciplinary treatment

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Cytotoxic agents
Thymoma and Thymic Cancer
Surgical oncology
Biological therapy
Radiation oncology
Presenter Aron Ghimessy
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors A.K. Ghimessy1, Á. Kelemen2, K. Török2, M. Gyugos2, B. Döme2
  • 1Thoracic Surgery, National Institute of Oncology, 1122 - Budapest/HU
  • 2Thoracic Surgery, National Institute of Oncology, Budapest/HU



Thymomas and thymic carcinomas are very rare tumors. According to the modern classification all thymic epithelial tumors are considered malignant. We know very little about thymomas and thymic cancers due to the rare occurrence and the very slow growth. Goals: I. Our first goal was to collect the data of the patients who underwent operation and/or local and systemic treatment in the National Institute of Oncology and the National Korányi Institute in the last fifteen years. We created a retrospective database and identified the important prognostic factors regarding overall and disease free survival. II. Our second goal was to create the first Hungarian prospective thymic malignancy database.


Altogether 90 patients were identified who underwent operation in the above mentioned two institutions between 2000 and 2015. We looked at the number of recurrences and calculated the overall and disease free survival. We reviewed the different Masaoka-Koga stages, WHO classifications and multidisciplinary treatment regiments. Our goal was to identify the main prognostic factors that affect the survival and later treatment.


Complete (R0) resection and the clinical stage (Masaoka–Koga) proved to be determinative prognostic factors regarding overall survival.


The multidisciplinary approach for the treatment of thymic malignancies proved to deliver good results. However, international collaborations are essential for high case number studies that will help to understand the complex molecular biology of thymic tumors and to create widely accepted protocols for diagnosis and treatment.

Clinical trial identification

Legal entity responsible for the study

National Institute of Oncology


National Institute of Oncology


All authors have declared no conflicts of interest.